You are here

Troxatyl Granted Fast Track Designation

SAN DIEGO, Oct. 19 /PRNewswire/ -- SGX Pharmaceuticals, Inc. (SGX) today announced that Troxatyl, an investigational drug in a pivotal Phase II/III clinical trial, has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for third-line treatment of Acute Myeloid Leukemia (AML) in adults. SGX announced in May 2005 that FDA had granted Troxatyl Orphan Drug Designation in the U.S. for the treatment of AML.

Fast Track programs are designed to facilitate the development and expedite the review of new drugs or biologics that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. Fast Track emphasizes the critical nature of close, early communication between the FDA and sponsors.

This designation may allow for the FDA to sanction company actions to expedite the development and review of a potential New Drug Application for Troxatyl to treat third-line AML. Fast Track designation also provides the potential to seek accelerated approval in which the FDA may grant market approval based on a determination that the drug effect on a surrogate endpoint is reasonably likely to predict clinical benefit.

About AML
AML is a blood cancer that increases in incidence with age. According to the American Cancer Society, AML represents approximately 90 percent of all acute leukemias in adults. In the United States, approximately 16,000 adult patients have AML with approximately 12,000 new patients diagnosed each year. Although induction chemotherapy, typically with Ara-C and an anthracycline, another class of chemotherapy drugs such as daunorubicin or idarubicin, results in complete remission in 50 percent to 60 percent of patients, relapse is common and long-term survival rates are less than 20 percent.

Source: SGX Pharmaceuticals, Inc.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation